- The 2022 awards, based on rigorous audits and employee responses, recognise companies for their COVID-19 leadership and management strategies
Riyadh, Saudi Arabia: Takeda, the R&D-driven global biopharmaceutical company, has been included among Saudi Arabia’s Best Workplaces™ List for 2022. Recognised for its award-winning company culture by the team at Great Place to Work®, Takeda in Saudi Arabia was listed among the top small and medium sized companies to work for in the Kingdom.
Based on a rigorous audit of each participating company including employee feedback, the recognition is based on confidential survey data assessing employee experiences of trust, innovation, company values and leadership. Companies are also evaluated on how well they are creating a For AllTM workplace experience, inclusive of all employees.
“Driven by our underlying goal to deliver better health and a brighter future for all, at Takeda, our corporate culture is underlined by our people-first approach. We want to create exceptional people experiences by prioritizing our staff’s health, wellbeing and career development, while creating an inclusive, growth-oriented environment,” said Rodrigo Rodriguez, General Manager, Middle East Cluster, Takeda,
“Fundamentally, we want to bring out the best in our employees and empower them to achieve excellence. It is only when we bring the best out in our people, that we can serve our patients best. We are delighted to be featured among the Best Workplaces™ List 2022 as a testament to our dedication and unwavering commitment to serve our communities,” he added.
Takeda was also recognised as a Great Place to Work® in the Middle East and follows numerous other accolades for its award-winning corporate culture, including certification as a Global Top Employer.
How Great Place to Work® determines the Best Workplaces™ in Saudi Arabia
Great Place to Work® is the global authority on workplace culture. It helps organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees. Great Place to Work® identifies the Best Workplaces in Saudi Arabia by analyzing companies’ workplace programs and surveying employees across the region about the key factors that create great workplaces for ALL™. To be considered, companies must first be certified as a Great Place to Work® and are based in the Gulf Region. A Culture Audit document must also be submitted for analysis which provided a more in-depth review of the workplace culture for the past year.
FOR UAE and KSA Companies rank in two size categories: Small and Medium, and Large.
Multinational organizations are also assessed on their efforts to create great workplaces across multiple countries in the region.
About Great Place to Work®
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Their employee survey platform empowers leaders with the feedback, real-time reporting, and insights they need to make strategic people decisions. Everything they do is driven by the mission to build a better world by helping every organization become a great place to work For AllTM.
About Takeda Pharmaceuticals
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
For more information